Peginesatide safe for anemia in patients undergoing dialysis

Peginesatide safe for anemia in patients undergoing dialysis
Peginesatide, a peptide-based erythropoiesis-stimulating agent, is safe and effective in patients with advanced chronic kidney disease and anemia as long as they are undergoing dialysis, according to two studies published in the Jan. 24 issue of The New England Journal of Medicine.

(HealthDay)—Peginesatide, a peptide-based erythropoiesis-stimulating agent, is safe and effective in patients with advanced chronic kidney disease and anemia as long as they are undergoing dialysis, according to two studies published in the Jan. 24 issue of The New England Journal of Medicine.

In the first study, Steven Fishbane, M.D., from the Hofstra North Shore-LIJ School of Medicine in Great Neck, N.Y., and colleagues analyzed data from 1,418 patients with and anemia undergoing who were treated with peginesatide or epoetin as part of two randomized open-label trials. The researchers found that peginesatide was non-inferior to epoetin in its ability to maintain hemoglobin levels, and the cardiovascular safety was similar in both groups.

In the second study, Iain C. Macdougall, M.D., from King's College Hospital in London, and colleagues analyzed data from 983 patients with advanced and anemia not undergoing dialysis who were treated with peginesatide or darbepoetin as part of two randomized open-label trials. The researchers found that peginesatide was non-inferior to darbepoetin in its ability to increase and maintain , but cardiovascular events and mortality were higher in patients receiving peginesatide.

"Peginesatide can be used for anemia correction in patients undergoing hemodialysis, in which case its efficacy profile is similar to the profiles of established erythropoiesis-stimulating agents, but concerns remain about its safety in patients not receiving hemodialysis," writes the author of an accompanying editorial.

Several authors from the first study disclosed financial ties to pharmaceutical companies, including Affymax and Takeda, which funded both studies.

More information: Full Text - Fishbane (subscription or payment may be required)
Full Text - Macdougall (subscription or payment may be required)
Editorial (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Anemia drug not helpful for kidney disease patients

Dec 22, 2009

An international study authored by a UT Southwestern Medical Center researcher has concluded that the anemia drug darbepoetin alfa works no better than a placebo in several other applications previously thought to be promising.

Recommended for you

Mali announces new Ebola case

1 hour ago

Mali announced Saturday a new case of Ebola in a man who is fighting for his life in an intensive care unit in the capital Bamako.

Plague outbreak kills 40 in Madagascar: WHO

2 hours ago

An outbreak of plague has killed 40 people in Madagascar, the World Health Organization said, warning that the disease could spread rapidly in the country's densely populated capital Antananarivo.

UN chief: Ebola cases in Mali a 'deep concern'

15 hours ago

The United Nations chief warned Friday that Ebola may be easing in part of West Africa but is still hitting hard in other areas and outpacing the international response.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.